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Time to consider ACE insertion/
deletion genotypes and individual 
renoprotective treatment in 
diabetic nephropathy?
PK Jacobsen,1 L Tarnow1 and H-H Parving1,2
One reason for the inadequacy of current renoprotective therapy and 
the persistent poor renal prognosis in diabetic nephropathy is the large 
interindividual variation in response to treatment. Genetic as well as 
non-genetic factors are known to influence treatment efficacy. This 
Commentary summarizes the impact of the angiotensin-converting 
enzyme (ACE) insertion/deletion polymorphism in the ACE gene on 
initiation and progression of diabetic nephropathy.
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Antihypertensive treatment has greatly 
improved the renal prognosis and survival 
of diabetic patients with nephropathy over 
the past few decades.1 More patients die 
of other causes, primarily cardiovascu-
lar, with well-preserved kidney function. 
However, despite therapy targeting ele-
vated blood pressure, albuminuria, hyper-
glycemia, and lipid abnormalities, patients 
with diabetic nephropathy still on average 
have a rate of decline in renal function 
three to six times that seen in individuals 
without renal disease.1,2 Consequently, 
diabetic nephropathy is still the most com-
mon cause of end-stage renal disease in the 
Western world. One reason for the inad-
equacy of current renoprotective therapy 
and the persistent poor renal prognosis 
is the large interindividual variation in 
response to fi rst-line therapy including 
drugs blocking the renin–angiotensin–
aldosterone system, as is demonstrated 
by the wide range in loss of glomerular 
filtration rate (GFR) in these subjects. 
Indeed, this ranges from 0 to 24 ml per 
minute per year during treatment.1,2 Well-
known non-genetic risk factors, namely 
elevated blood pressure, albuminuria, 
poor glycemic control, and hypercholes-
terolemia, explain about 30%–50% of this 
variation.1,2 Characterization of additional 
risk factors is the key to understanding the 
progression of diabetic nephropathy, to 
identifying high-risk individuals, and to 
improving treatment and overall progno-
sis. Besides the non-genetic factors, drug 
responses are also known to be infl uenced 
by inherited factors;3 this fi eld is known as 
pharmacogenomics.3 Th e basic concept is 
simple: a drug interacts with its target, for 
instance an enzyme or a receptor. When 
genetic alteration leads to modifi ed target 
availability or function, the drug response 
is modifi ed as well. However, this con-
cept also involves more complex relations 
such as interplay between several genetic 
sites during therapy and the direct eff ects 
of drugs on gene transcription. Basically, 
pharmacogenomics is the integrated 
eff ects of the genome on drug response. In 
this issue, So et al.4 provide more evidence 
supporting the importance of pharmacog-
enomics in diabetic patients by reporting 
an impact of the angiotensin-converting 
enzyme (ACE) insertion/deletion poly-
morphism in the renin–angiotensin sys-
tem on response to ACE inhibition in 2089 
Chinese type 2 diabetic patients with vari-
ous degrees of albuminuria.
Activation of the renin–angiotensin–
aldosterone system is important in the 
initiation and progression of diabetic 
nephropathy.1 Th e ACE insertion (I)/dele-
tion (D) polymorphism infl uences the 
systemic and renal activity of the renin–
angiotensin system, as patients carrying 
the D allele have increased systemic and 
renal ACE levels, whereas patients with the 
II genotype have the lowest ACE concen-
trations.1 A recent metaanalysis of 14 727 
diabetic patients included in case-control 
studies from 1994 to 2004 confi rms a sta-
tistically signifi cant protective role of the 
II genotype in the development of diabetic 
nephropathy;5 the eff ect was most pro-
nounced in Asians with type 2 diabetes, 
followed by Caucasians with types 1 and 
2 diabetes.5 Th e relation between the ACE 
I/D polymorphism and progression of 
diabetic nephropathy has been studied 
during the past 10 years. Minimal data 
exist on the impact of ACE gene poly-
morphism during the natural course of 
diabetic nephropathy without any anti-
hypertensive treatment. In 59 normoten-
sive type 1 diabetic patients with diabetic 
nephropathy and stable renal function 
(decline in GFR of about 1 ml per minute 
per year), we found no relation between 
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loss of GFR and the ACE I/D polymor-
phism.1 However, it should be stressed 
that this population was highly selected, 
as they had the lowest blood pressure, had 
preserved kidney function, and carried the 
best renal prognosis.1 More data exist on 
the ACE I/D polymorphism during anti-
hypertensive treatment. In two observa-
tional follow-up studies of type 1 diabetic 
patients with diabetic nephropathy receiv-
ing ACE inhibitors (n = 35 and n = 169), 
we have reported an adverse eff ect of the 
D allele on kidney function and time to 
end-stage renal disease.6,7 Th is is in agree-
ment with an analysis from the EURO-
DIAB Controlled Trial of Lisinopril in 
IDDM (EUCLID) (n = 530) demonstrat-
ing a decline in urinary albumin excre-
tion as a response to ACE inhibition in II 
patients but not in patients with ID or DD 
genotypes.8 Other, albeit smaller, studies 
have shown confl icting results in type 1 
diabetic patients.1 In Caucasian and Asian 
type 2 patients with diabetic nephropathy 
receiving antihypertensive therapy, includ-
ing ACE inhibitors but not angiotensin II 
receptor blockers (ARBs), a deleterious 
eff ect of the D allele has also been shown.1 
In contrast, case-control studies in both 
type 1 and type 2 diabetic patients com-
paring genotype frequencies in patients 
with end-stage renal disease and control 
subjects are vulnerable to selection bias 
and selective drop-out of patients carrying 
deleterious genotypes. Consequently, such 
studies have had confl icting results.1 Th e 
prospective study by So et al.4 confi rms 
and extends earlier observations in Asian 
type 2 patients by demonstrating that the 
DD genotype enhances the development 
of renal end points in diabetic patients. 
Furthermore, the study demonstrates 
a benefi cial eff ect of ACE inhibitors on 
mortality and renal end points, which in 
both cases are more evident in patients 
with the II and ID genotypes than in DD 
patients.4 Unfortunately, the type and fre-
quency of antihypertensive therapies are 
not reported in detail in this study. Other 
limitations to the study are the non-ran-
domized design with regard to antihy-
pertensive therapy and the fact that the 
patients were not receiving the current 
fi rst-line therapy for treatment of type 2 
diabetes, namely ARBs. Taken together, 
however, the literature at present indicates 
that, in patients with diabetic nephropa-
thy, the ACE I/D polymorphism predicts 
the effi  cacy of both ACE inhibition and 
antihypertensive therapy that do not block 
the renin–angiotensin–aldosterone sys-
tem. In patients with non-diabetic renal 
disease, the importance of the ACE I/D 
polymorphism is less clear.9
What, then, are the next steps? How 
do we improve the treatment strategy in 
diabetic patients with the DD genotype, 
and is there a diff erence in the impact of 
the ACE I/D genotype on treatment with 
ACE inhibitors versus ARBs? We do have 
some indications of the likely answers to 
these questions. As is mentioned above, 
the ACE I/D polymorphism directly infl u-
ences circulating levels of ACE, the com-
ponent targeted by ACE inhibitors. Th e 
production of ACE is upregulated during 
chronic ACE inhibition,1 but unfortu-
nately we do not know whether this rela-
tion is aff ected by genotype. Th erefore, the 
current treatment strategy of ACE inhi-
bition in patients with the DD genotype 
may be insuffi  cient to block an activated 
renin–angiotensin system, and this inter-
action might be neutralized by treatment 
with ARBs or ultra-high doses of ACE 
inhibitors. Consistent with this view, in a 
prospective, double-blind study of 54 type 
1 diabetic patients with II (n = 26) or DD 
(n = 28) genotypes who were followed for 
36 months, we have previously reported 
that the short-term antialbuminuric 
response as well as the long-term renopro-
tective response to losartan (rate of decline 
in GFR) was not diff erent between the II 
and DD genotypes.10 Th e loss of GFR was 
approximately 3 ml per minute per year 
in both genotypes, which indicates effi  -
cient treatment and a potential advantage 
of ARBs over ACE inhibitors in patients 
with the DD genotype. However, for a 
defi nite answer to this question, a study 
including patients with diff erent ACE I/D 
genotypes and treatment with both ACE 
inhibitors and ARBs is needed. In type 2 
diabetic patients, no data are yet available 
on the interaction between genotypes and 
ARBs, but results from the Reduction of 
Endpoints in NIDDM with the Angio-
tensin II Antagonist Losartan (RENAAL) 
study and the Irbesartan Type 2 Diabetic 
Nephropathy Trial (IDNT) may elucidate 
these issues.
As described, the ACE I/D polymor-
phism interacts with antihypertensive 
therapy, development and progression 
of diabetic nephropathy, and ethnicity. 
In addition, we have previously demon-
strated a potential synergistic interplay 
among the ACE I/D polymorphism, the 
angiotensinogen-M235T polymorphism, 
and the angiotensin II type 1 receptor 
(A1166→C) polymorphism in type 1 dia-
betic patients with nephropathy result-
ing in deleterious renal outcomes.7 Th e 
D allele of the ACE I/D polymorphism 
was assumed to be within a primary sus-
ceptibility locus and the other polymor-
phisms to be within loci reinforcing the 
impact of the D allele.7 However, these 
fi ndings need to be confi rmed, and mech-
anisms explaining the possible interac-
tion remain to be clarifi ed. Finally, the 
functional signifi cance of the polymor-
phism may also be infl uenced by gender9 
and environmental factors not related 
to drug therapy, such as sodium intake, 
a known regulator of renin–angiotensin 
system activity. Among healthy subjects, 
the eff ect of ACE inhibitors as well as the 
renal vascular response to angiotensin I 
is modifi ed by dietary sodium intake in 
DD genotype patients but not in patients 
with the other genotypes.11
In conclusion, the ACE I/D polymor-
phism interacts with several genetic and 
non-genetic factors as well as with the 
type of renoprotective treatment. This 
is an example of why future therapy in 
Table 1 | The ACE I/D polymorphism in diabetic nephropathy: key points
The ACE I/D polymorphism influences the systemic and renal activity of the renin–angiotensin system
II genotype protects against the development of diabetic nephropathy
DD genotype predicts poor renal response to ACE inhibitors and antihypertensive agents not 
blocking the renin–angiotensin system
Future studies are needed to show whether treatment with angiotensin II receptor blockers can 
neutralize the adverse effect of the D allele
In addition, the ACE I/D polymorphism interacts with other genetic and non-genetic factors (e.g., 
sodium intake), favoring an individualized treatment strategy
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diabetic nephropathy needs to be based 
on individualized renoprotective strate-
gies and not only on diagnosis. Th ere is 
a specifi c need to further investigate the 
interaction between the ACE I/D poly-
morphism and ARBs, especially in type 2 
diabetic patients with nephropathy. Hope-
fully, more focus on individual treatment 
strategies will diminish the number of 
poor treatment responders and result in 
further improvement in renal prognosis 
as well as survival in the growing popu-
lation of patients suff ering from diabetic 
nephropathy worldwide.
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Cellular contributions to 
glomerular size-selectivity
WM Deen1
The glomerular capillary wall permits free passage of  low-molecular-
weight solutes, while severely restricting large proteins. Although 
both cell layers (endothelium and epithelium) almost certainly 
contribute to this size-selectivity, their relative importance has been 
difficult to assess. The finding by Rippe et al. of an inverse relationship 
between the sieving coefficient of Ficoll and glomerular filtration rate 
sheds light on this.
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In this issue, Rippe et al.1 show that 
if glomerular filtration rate (GFR) 
in healthy rats is increased from low 
(hydropenic) to normal levels, then the 
sieving coeffi  cient of Ficoll is decreased. 
Th e sieving coeffi  cient (θ, the Bowman’s 
space-to-plasma concentration ratio) is 
the principal measure of how eff ective the 
glomerular barrier is at retaining a given 
macromolecule within the circulation. 
Ficoll is a polysaccharide that approxi-
mates an ideal, neutral sphere and is 
therefore the preferred marker of barrier 
size-selectivity. Numerous studies over 
the years with experimental animals or 
humans have shown that θ decreases with 
increasing molecular size, but informa-
tion on the dependence of θ on GFR has 
been limited. Th e present fi nding that θ 
decreases with increasing GFR for a wide 
range of Ficoll sizes in vivo is consistent 
with recent results for globular proteins2 
and with earlier data for dextran.3
As noted by Rippe et al.,1 the inverse 
dependence of θ on fi ltration velocity is a 
hallmark of a membrane operating under 
conditions in which diff usion infl uences 
sieving. At fi ltration rates low enough 
to allow diff usion to compete with bulk 
fl ow (convection) of the solute, θ is larger 
than it would be if diff usion were absent. 
If fi ltration rates are very low, then even 
a molecule that has difficulty getting 
through the barrier will have time to 
equilibrate between fi ltrate and reten-
tate, and θ → 1. Th e intrinsic selectivity 
of the barrier is then masked. At the other 
extreme, if water fi ltration is so rapid as to 
make diff usion negligible, then θ will fall 
to a minimum value that is determined by 
the membrane structure and by the char-
acteristics (for example, size and shape) 
of the test molecule. Th at minimum value 
is sometimes written as 1 – σ, where σ is 
the refl ection coeffi  cient, and is denoted 
also as W, the convective hindrance fac-
tor.4 Using the latter notation, the sieving 
behavior of a homogeneous membrane is 
summarized by saying that W ≤ θ ≤ 1, 
the lower values of θ corresponding to 
the highest water filtration rates. This 
assumes that concentration polarization 
at the upstream side of the membrane is 
negligible, as appears to be true for the 
glomerulus.5




in which Pe is the Peclet number, a 
measure of the importance of convec-
tion relative to diff usion.4 Th e diff usion 
θ =                                         
W
(1 – e–Pe) + We–Pe
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